IOBT

IO Biotech Inc

Apr 06 • 04:00PM ET

0.0480

0.0000 0.00 %

Healthcare • Biotechnology • Denmark • NASD

Peers: ARGX FATE TVRD APLS AFMD KURA ANAB ALLK ALXO CTMX

Index	-	P/E	-	EPS (ttm)	-1.34	Insider Own	16.12%	Shs Outstand	69.69M	Perf Week	-18.23%
Market Cap	3.45M	Forward P/E	-	EPS next Y	-0.12	Insider Trans	0.00%	Shs Float	60.35M	Perf Month	-82.86%
Enterprise Value	-9.09M	PEG	-	EPS next Q	-	Inst Own	40.08%	Short Float	4.67%	Perf Quarter	-92.49%
Income	-88.35M	P/S	-	EPS this Y	59.09%	Inst Trans	-10.19%	Short Ratio	0.14	Perf Half Y	-90.04%
Sales	0.00M	P/B	3.67	EPS next Y	66.67%	ROA	-136.03%	Short Interest	2.82M	Perf YTD	-92.12%
Book/sh	0.01	P/C	0.11	EPS next 5Y	-	ROE	-240.48%	52W High	2.79 -98.28%	Perf Year	-95.12%
Cash/sh	0.43	P/FCF	-	EPS past 3/5Y	17.72% -25.33%	ROIC	-484.32%	52W Low	0.03 73.29%	Perf 3Y	-97.51%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	47.81% 24.07%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	2.36%	Oper. Margin	-	ATR (14)	0.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.01	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	23.79	Recom	5.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.01	EPS Q/Q	65.65%	SMA20	-72.22%	Beta	0.83	Target Price	0.36
Payout	-	Debt/Eq	19.91	Sales Q/Q	-	SMA50	-82.21%	Rel Volume	0.00	Prev Close	0.05
Employees	-	LT Debt/Eq	19.04	Earnings	Mar 04	SMA200	-94.95%	Avg Volume	20.39M	Price	0.05
IPO	Nov 05, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	34.36% -	Trades		Volume	481,589,632	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-26-26	Downgrade	Piper Sandler	Overweight → Neutral	$0.50
Jan-08-26	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$0.36
Sep-30-25	Downgrade	TD Cowen	Buy → Hold
Sep-30-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$0.39

Apr-06-26 10:30AM	BC-Most Active Stocks (Associated Press) +48.61%
Mar-31-26 10:30AM	BC-Most Active Stocks (Associated Press) -65.95%
Feb-13-26 09:55AM	Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom Fishing (Zacks)
Jan-30-26 08:05AM	IO Biotech Provides Corporate Update (GlobeNewswire) -8.28%
Jan-27-26 08:00AM	Piper downgrades IO Biotech amid strategic alternatives evaluation (TipRanks) +6.16%
05:38AM	Loading…
Jan-21-26 05:38AM	Moderna cancer vaccine holds up; IO Biotech considers a sale (BioPharma Dive) -59.74%
05:30AM	IO Biotech Announces Exploration of Strategic Alternatives (GlobeNewswire)
Dec-15-25 04:05PM	IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications (GlobeNewswire) -12.54%
Nov-26-25 10:46AM	IO Biotech Announces Participation in Upcoming December Investor Conferences (GlobeNewswire)
Nov-19-25 12:00PM	IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why (Zacks) -8.90%
Nov-14-25 08:05AM	IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-12-25 08:30AM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -6.00%
Nov-07-25 09:00AM	IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) +6.96%
Oct-27-25 08:30AM	Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology (PR Newswire) -9.11%
Oct-20-25 02:30AM	IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 (GlobeNewswire) +25.18%
09:00AM	Loading…
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire) +6.83%
Oct-01-25 06:00AM	FDA officials comments spark Aurinia sell-off; Halozyme buys a biotech (BioPharma Dive)
Sep-29-25 07:05AM	IO Biotech Provides Update Following Pre-BLA Meeting with FDA (GlobeNewswire) -76.89%
Sep-23-25 08:05AM	IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025 (GlobeNewswire) +7.38%
Sep-15-25 08:30AM	Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth (PR Newswire) -11.54%
Sep-04-25 08:05AM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-03-25 12:00PM	IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-26-25 08:39AM	H.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14 (Insider Monkey)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-14-25 04:05PM	IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) +68.75%
12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire)
Aug-11-25 01:23PM	IO Biotech to pursue cancer vaccine approval despite Phase III miss (Clinical Trials Arena) -41.99%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:02AM	IO Biotech sees path forward for skin cancer vaccine despite study setback (BioPharma Dive)
08:00AM	IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio plus KEYTRUDA (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed (GlobeNewswire)
08:00AM	Loading…
Aug-10-25 08:00AM	IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma (GlobeNewswire)
May-28-25 09:55AM	IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
May-20-25 08:05AM	IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 12:11PM	IO Biotech price target raised to $14 from $12 at H.C. Wainwright (TipRanks)
May-14-25 08:05AM	IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Apr-26-25 03:05PM	IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Apr-25-25 01:00PM	IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 (GlobeNewswire)
Mar-25-25 04:35PM	IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +17.00%
Mar-18-25 08:00AM	IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025 (GlobeNewswire)
Mar-04-25 04:17PM	IO Biotech Reports 2024 Business Highlights (GlobeNewswire) +5.91%
Feb-23-25 12:07PM	IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference (GlobeNewswire)
Feb-20-25 08:05AM	IO Biotech to Present at the 45th Annual Cowen Health Care Conference (GlobeNewswire) +11.00%
Feb-04-25 08:05AM	IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate (GlobeNewswire) +6.74%
Jan-10-25 11:10AM	IO Biotech enrols all subjects in Phase II trial of cancer combination therapy (Clinical Trials Arena)
Jan-09-25 08:05AM	IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer (GlobeNewswire)
Dec-20-24 08:05AM	IO Biotech secures up to 57.5 million in debt financing from the European Investment Bank (GlobeNewswire)
Nov-12-24 07:05AM	IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -11.68%
Nov-11-24 04:05PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 10:00AM	IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study (GlobeNewswire) +6.03%
Oct-04-24 09:00AM	IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) +13.86%
Sep-14-24 02:30AM	IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer (GlobeNewswire)
Sep-02-24 06:53AM	IO Biotechs melanoma treatment trial to continue after IDMC review (Clinical Trials Arena)
Aug-30-24 04:05PM	IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma (GlobeNewswire) -33.33%
Aug-26-24 04:05PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 07:05AM	IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +17.69%
Jul-25-24 04:05PM	IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024 (GlobeNewswire)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
May-23-24 08:30AM	IO Biotech to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 01:54PM	IOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024 (InvestorPlace)
07:55AM	IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-24-24 04:30PM	IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-15-24 08:30AM	IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness (GlobeNewswire)
Apr-09-24 12:00PM	IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 (GlobeNewswire)
Apr-05-24 08:30AM	IO Biotech Appoints Faical Miyara, Ph.D., as Chief Business Officer (GlobeNewswire)
08:30AM	IO Biotech Appoints Fai al Miyara, Ph.D., as Chief Business Officer (GlobeNewswire)
Mar-07-24 02:01PM	IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials (GuruFocus.com) +6.63%
Mar-06-24 04:11PM	IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-05-24 10:52PM	IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023 (InvestorPlace)
04:40PM	IO Biotech Announces 2023 Fourth-Quarter and Year-End Results (GlobeNewswire)
Feb-26-24 04:05PM	IO Biotech to Present at 44th Annual Cowen Health Care Conference (GlobeNewswire)
Dec-21-23 08:30AM	IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial (GlobeNewswire)
Nov-13-23 08:12AM	IO Biotech Announces 2023 Third Quarter Results (GlobeNewswire)
08:00AM	IO Biotech Appoints Helen Collins, MD, to its Board of Directors (GlobeNewswire)
Nov-10-23 08:00AM	IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma (GlobeNewswire)
Nov-08-23 04:30PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-01-23 08:30AM	IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +8.38%
Oct-23-23 01:00AM	Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress (GlobeNewswire) -5.05%
Oct-03-23 04:30PM	IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire) +10.22%
Sep-12-23 08:05AM	IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer (GlobeNewswire) -13.20%
Sep-06-23 08:35AM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 08:59AM	10 Best New Penny Stocks to Buy Now (Insider Monkey)
Aug-16-23 09:01PM	Stonepine Capital Management, LLC Acquires New Stake in IO Biotech Inc (GuruFocus.com)
Aug-11-23 08:30AM	IO Biotech Announces 2023 Second Quarter Results (GlobeNewswire)
08:05AM	IO Biotech Appoints Heidi Hunter to its Board of Directors (GlobeNewswire)
Aug-08-23 08:05AM	IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023 (GlobeNewswire)
Aug-07-23 08:30AM	IO Biotech, Inc. Announces $75 Million Private Placement Financing (GlobeNewswire)
Jul-28-23 08:05AM	IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center (GlobeNewswire)
Jul-25-23 04:05PM	IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer (GlobeNewswire)
Jul-18-23 04:05PM	IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer (GlobeNewswire)
Jun-15-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally Over 300% (TipRanks) +27.33%
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-14-23 12:42PM	Why Are IO Biotech Shares Trading Lower Today (Benzinga) -26.48%
08:00AM	IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone (GlobeNewswire)
Jun-01-23 08:30AM	IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead (GlobeNewswire)
May-30-23 04:35PM	IO Biotech to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:05PM	IO Biotech Announces 2023 First-Quarter Results (GlobeNewswire) +9.69% -7.91%
May-02-23 07:22AM	Is IO Biotech (NASDAQ:IOBT) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-22-23 06:14AM	The Chief Financial Officer of IO Biotech, Inc. (NASDAQ:IOBT), Amy Sullivan, Just Bought A Few More Shares (Simply Wall St.)
Mar-14-23 04:11PM	IO Biotech Announces 2022 Fourth-Quarter and Year-End Results (GlobeNewswire) -7.79%

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hunter Heidi	Director	May 30 '25	Buy	1.39	15,000	20,884	15,000	Jun 02 07:53 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IOBT

IO Biotech Inc

Upgrade your Finviz experience